CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 28 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2015. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $14,897,960 | +78.2% | 630,735 | +12.5% | 0.00% | +50.0% |
Q3 2023 | $8,360,946 | +33.2% | 560,761 | -2.2% | 0.00% | +100.0% |
Q2 2023 | $6,275,937 | -6.9% | 573,145 | -25.9% | 0.00% | -50.0% |
Q1 2023 | $6,743,577 | +1162.2% | 773,346 | +807.5% | 0.00% | – |
Q4 2022 | $534,292 | +64899.0% | 85,214 | -63.7% | 0.00% | – |
Q3 2022 | $822 | +9.2% | 234,722 | -8.0% | 0.00% | – |
Q2 2022 | $753 | -100.0% | 255,043 | -54.8% | 0.00% | – |
Q1 2022 | $1,754,000 | -10.1% | 564,116 | -2.3% | 0.00% | – |
Q4 2021 | $1,952,000 | +82.4% | 577,120 | +97.0% | 0.00% | – |
Q3 2021 | $1,070,000 | +72.3% | 292,964 | +105.8% | 0.00% | – |
Q2 2021 | $621,000 | +47.5% | 142,363 | +53.5% | 0.00% | – |
Q1 2021 | $421,000 | -92.2% | 92,768 | -90.1% | 0.00% | -100.0% |
Q4 2020 | $5,401,000 | +642.9% | 940,982 | +835.6% | 0.00% | – |
Q3 2020 | $727,000 | -71.3% | 100,578 | -86.1% | 0.00% | -100.0% |
Q2 2020 | $2,531,000 | +136.5% | 724,975 | +0.3% | 0.00% | – |
Q1 2020 | $1,070,000 | +43.4% | 722,501 | +89.9% | 0.00% | – |
Q4 2019 | $746,000 | -43.7% | 380,401 | +46.9% | 0.00% | – |
Q3 2019 | $1,326,000 | +31.7% | 259,030 | +84.0% | 0.00% | – |
Q2 2019 | $1,007,000 | -63.8% | 140,752 | -32.8% | 0.00% | -100.0% |
Q1 2019 | $2,782,000 | +273.9% | 209,495 | +121.6% | 0.00% | – |
Q4 2018 | $744,000 | +2.5% | 94,549 | +44.3% | 0.00% | – |
Q3 2018 | $726,000 | -10.3% | 65,508 | +8.6% | 0.00% | – |
Q2 2018 | $809,000 | -85.9% | 60,297 | -86.4% | 0.00% | -100.0% |
Q1 2018 | $5,746,000 | +2816.8% | 442,343 | +1966.3% | 0.00% | – |
Q4 2017 | $197,000 | +515.6% | 21,407 | +29.3% | 0.00% | – |
Q3 2016 | $32,000 | -92.3% | 16,554 | -61.1% | 0.00% | – |
Q4 2014 | $418,000 | – | 42,563 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |